Talacotuzumab

(Synonyms: JNJ 56022473; CSL 362)
1 Cited Publications
고객리뷰

Based on 1 publication(s) in Google Scholar

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • 보관:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • 순도&문서
  • References
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Talacotuzumab

More
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00